{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:04:18Z","timestamp":1792728258277,"version":"4.5.0"},"reference-count":6,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Ceftaroline is a new cephalosporin with bactericidal activity against resistant Gram-positive organisms, including methicillin-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            (MRSA) and penicillin-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Streptococcus pneumoniae<\/jats:named-content>\n            , as well as common Gram-negative organisms. This study tested the prodrug, ceftaroline fosamil, against a penicillin-sensitive and a penicillin-resistant strain of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. pneumoniae<\/jats:named-content>\n            in an experimental rabbit meningitis model. The penetration of ceftaroline into inflamed meninges was approximately 14%. Ceftaroline fosamil was slightly superior to ceftriaxone against the penicillin-sensitive strain and significantly superior to the combination of ceftriaxone and vancomycin against the penicillin-resistant strain.\n          <\/jats:p>","DOI":"10.1128\/aac.00286-13","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T02:42:23Z","timestamp":1373337743000},"page":"4653-4655","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of Ceftaroline Fosamil against Penicillin-Sensitive and -Resistant Streptococcus pneumoniae in an Experimental Rabbit Meningitis Model"],"prefix":"10.1128","volume":"57","author":[{"given":"P.","family":"Cottagnoud","sequence":"first","affiliation":[{"name":"Clinic of Internal Medicine, Clinic Sonnenhof, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cottagnoud","sequence":"additional","affiliation":[{"name":"Zieglerspital, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Acosta","sequence":"additional","affiliation":[{"name":"Zieglerspital, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stucki","sequence":"additional","affiliation":[{"name":"Berner Reha Zentrum, Heiligenschwendi, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"E070315.3","article-title":"Trends in antimicrobial resistance in Europe: update of EARSS results","volume":"12","author":"de Kraker M","year":"2007","unstructured":"de KrakerMvan de Sande-BruinsmaN. 2007. Trends in antimicrobial resistance in Europe: update of EARSS results. Euro Surveill. 12:E070315.3.","journal-title":"Euro Surveill."},{"key":"e_1_3_2_3_2","first-page":"57","article-title":"Initial management of acute bacterial meningitis in adults: summary of IDSA guidelines","volume":"3","author":"Beckham JD","year":"2006","unstructured":"BeckhamJDTylerKL. 2006. Initial management of acute bacterial meningitis in adults: summary of IDSA guidelines. Rev. Neurol. Dis. 3:57\u201360.","journal-title":"Rev. Neurol. Dis."},{"key":"e_1_3_2_4_2","volume-title":"Antibiotics in laboratory medicine","author":"Lorian V","year":"1996","unstructured":"LorianV. 1996. Antibiotics in laboratory medicine, 4th ed. Williams & Wilkins, Philadelphia, PA.","edition":"4"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.6.4.437"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.1.63"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100960050421"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00286-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00286-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:31:21Z","timestamp":1645482681000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00286-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":6,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1128\/AAC.00286-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.00286-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"2013-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-07-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-09-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}